Navigation Links
Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
Date:8/17/2010

VANCOUVER, Canada, Aug. 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

XEN402 has been developed by Xenon as a topical ointment formulation and recently concluded a 21-day cumulative dose safety tolerability phase 1 study in normal human volunteers.  The product was well tolerated and achieved good drug concentrations in the skin.  Topical XEN402 is being developed by Xenon for painful neuropathic disorders such as PHN and targets the sodium channel sub-type Nav1.7. This target is highly expressed in sensory nerve endings and its expression has been shown to be up-regulated in chronic painful conditions such as PHN.

"This is an important step forward in the development of topical XEN402," said Xenon President & CEO, Dr. Simon Pimstone.  "This is a truly unique product built on our genetic studies that showed Nav1.7 deficient humans are completely unable to feel pain. By treating pain locally at its source through Nav1.7 block, topical XEN402 could be a very effective and safe treatment option. Our pre-clinical data show excellent efficacy with topical XEN402 in multiple inflammatory and neuropathic pain models when compared to other topical agents and additive effects to existing oral pain treatments.  We are excited by these findings as the product could eventually treat multiple chronic painful conditions.  This progress signifies another example of Xenon transitioning its target discovery engine to human proof-of-concept trials."

Xenon's VP, Clinical Development, Dr. Paul Goldberg referred to topical XEN402 as a "potentially transformative therapy as leading agents have significant side effects and often leave many patients still in pain.  As such there is a large unmet medical need for a novel analgesic that is both effective and safe. We see topical XEN402 being used both a
'/>"/>

SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
2. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
3. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
4. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
8. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
9. Angiotech Pharmaceuticals Announces Conference Call and Webcast
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Can economic ... from work motivate members of the public to increase ... including Johns Hopkins Carey Business School Assistant ... yes. Pointing to a large body of recent research ... the May 24, 2013, issue of Science that the ...
(Date:5/23/2013)... 2013 Graphite Metallizing Corporation announces ... mounted in stainless steel pillow blocks. This series ... with the application and installation versatility of pillow ... work exceptionally well when submerged in water, ... such as acids, alkalies, hydrocarbons, black liquor, and ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... Inc., a,privately held biopharmaceutical company developing anti-inflammatory drugs,announced ... 500 patient FRANCIS,(Fewer Recurrent Acute coronary events with ... the impact of,varespladib (A-002) when administered to patients ... event. , "We are ...
... a pioneer in the development of novel products to ... announced that Ted Hibben has joined the company as ... Coley Pharmaceutical Group, where he was most recently vice ... a key role in the company,s $233 million acquisition ...
... Houlihan Smith & Co., Inc.,acted as the exclusive ... Inc. d/b/a NJOY, as announced by Charles Botchway, ... & Company, Inc. The,transaction was led by ... disclosed. , "We appreciate ...
Cached Biology Technology:Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 2Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 3Cequent Names Ted Hibben Chief Business Officer 2Cequent Names Ted Hibben Chief Business Officer 3Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc. 2
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
(Date:5/23/2013)... per year, carrying more than 284 million tons of cargo, ... dollars in toll fees for the Panama Canal Authority. Each ... of water are used from Gatun Lake, which is also ... in the isthmus. , However, the advent of very ... the ships at sea, has demanded change. The Panama Canal ...
(Date:5/23/2013)... at Rollins School of Public Health at Emory ... of Technology, have received a $4 million grant ... at Emory University (Health and Exposome Research Center: ... exposome-based center grant awarded in the United States. ... the National Institute of Environmental Health Sciences (NIEHS) ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... have determined that the presence of the rare element ... increase to the consumption of refined platinum, the primary ... cars to reduce smog. A volatile form of osmium ... normal operation of cars, and it gets dispersed globally ...
... Computer engineers at Washington University in St. Louis ... and computing by coupling USB-based ultrasound probe technology ... platform and a medical imaging device that fits ... D. Richard, Ph.D., Washington University Associate Professor of ...
... The bacteria responsible for chronic infections in cystic fibrosis ... surface to start building a structure that helps the ... Scientists have determined that the bacterial cell-surface sugar, ... of the bacterium as a helix, providing a structure ...
Cached Biology News:Increasing levels of rare element found worldwide 2Ultrasound imaging now possible with a smartphone 2Ultrasound imaging now possible with a smartphone 3Sugar on bacteria surface serves as base for a web of resistance 2Sugar on bacteria surface serves as base for a web of resistance 3